

5/15/09

Contact: Shore Psychiatric Associates  
Beth Parker-O'Brien, LCSW-C  
(410) 820-4005  
geripsych@verizon.net

### **For Immediate Release**

## **Shore Psychiatric Associates Enrolling Patients in Study of Investigational Therapy for Alzheimer's Disease**

Easton, MD, [INSERT DATE] – Shore Psychiatric Associates today announced it has begun enrolling patients in the CONCERT study, a new late-stage clinical study that will evaluate the safety and efficacy of the investigational drug Dimebon™ as a treatment for mild-to-moderate Alzheimer's disease for patients who are on a stable dose of donepezil.

According to new estimates from the Alzheimer's Association, more than 5 million people in the United States are living with Alzheimer's disease<sup>1</sup>, a progressive, debilitating and deadly disease that destroys brain cells and affects areas of the brain involved in memory, cognition, judgment, language and behavior. As the baby boomer population ages, the incidence of Alzheimer's disease is expected to increase dramatically. Currently available therapies for Alzheimer's treat the symptoms with modest effect, and there is no evidence that these medications alter the course of the underlying disease process.

### **About Dimebon**

Dimebon is an investigational therapy in clinical development for the treatment of Alzheimer's disease. It targets Alzheimer's disease differently than currently available therapies. In a pre-clinical study in which brain cells were exposed to different toxins, including beta amyloid, Dimebon was shown to stabilize mitochondrial function, a vital element of neuron function and survival. Medivation, Inc., the company developing Dimebon and sponsoring the CONCERT study, previously announced efficacy and safety results from the first pivotal 12-month trial suggesting that Dimebon improved the clinical course of Alzheimer's disease.

Patients taking Dimebon showed improvement over patients taking placebo in each of the five most important aspects of Alzheimer's: memory, thinking, behavior, activities of daily living (such as eating and toilet use) and overall function. These improvements were seen after as little as 12 weeks of study drug and were generally maintained over a full year on Dimebon. Dimebon was well tolerated throughout the one-year treatment period.

### **About the CONCERT Study**

The CONCERT study will enroll 1050 patients in the United States – as well as sites in Europe, Australia and South America – to test the effects of Dimebon in patients with mild-to-moderate

---

<sup>1</sup> 2008 Alzheimer's Disease Facts and Figures, Alzheimer's Association, [http://www.alz.org/national/documents/report\\_alzfactsfigures2008.pdf](http://www.alz.org/national/documents/report_alzfactsfigures2008.pdf)

Alzheimer's disease. The study will evaluate the impact of Dimebon on cognition (thinking and awareness), memory, daily functioning, behavior and the ability to care for oneself.

Patients age 50 and older who are currently stable on donepezil and not taking any other Alzheimer's prescription medications may be eligible for the one year study. Patients will randomly be chosen to receive either Dimebon or placebo (sugar pill), which does not contain active medicine. After one year of treatment, all patients – including those receiving placebo – will be offered the opportunity to receive Dimebon in an extension trial until marketing authorization.

For more information on eligibility and enrollment, patients and caregivers can call Shore Psychiatric Associates at (410) 820-4005.

# # #